Net Loss Per Share (Tables)

3 Months Ended

Mar. 31, 2022

Earnings Per Share [Abstract]

Schedule of Comparison of Basic and Fully Diluted Net Loss Per Share

The respective “Net loss per share - attributable to PAVmed Inc. - basic and diluted” and “Net loss per share - attributable to PAVmed Inc. common stockholders - basic and diluted” - for the periods indicated - is as follows:

	Three Months Ended March 31,
	2022			2021
Numerator
Net loss - before noncontrolling interest	$	(19,633	)	$	(10,110	)
Net loss attributable to noncontrolling interest		2,761			679
Net loss - as reported, attributable to PAVmed Inc.	$	(16,872	)	$	(9,431	)
Series B Convertible Preferred Stock dividends – earned	$	(68	)	$	(75	)
Net loss attributable to PAVmed Inc. common stockholders	$	(16,940	)	$	(9,506	)
Denominator
Weighted average common shares outstanding, basic and diluted		86,336,427			73,954,126
Loss per share
Basic and diluted
Net loss - as reported, attributable to PAVmed Inc.	$	(0.20	)	$	(0.13	)
Net loss attributable to PAVmed Inc. common stockholders	$	(0.20	)	$	(0.13	)

Schedule of Antidilutive Securities Excluded from Computation of Diluted Earnings Per Share

	March 31,
	2022		2021
Stock options and restricted stock awards		12,368,292		8,539,362
Series Z Warrants		11,937,450		15,954,722
Series W Warrants		—		381,818
Series B Convertible Preferred Stock		1,136,210		1,241,438
Total		25,441,952		26,117,340